Endoproteolytic cleavage of TUG regulates GLUT4 glucose transporter translocation*

Jonathan S. Bogan1,2, Bradley R. Rubin1,2, Chenfei Yu1, Michael G. Löffler1, Charisse M. Orme1,2, Jonathan P. Belman1,2, Leah J. McNally1, Mingming Hao1, and James A. Cresswell1

1From the Section of Endocrinology and Metabolism, Department of Internal Medicine, and 2Department of Cell Biology, Yale University School of Medicine, New Haven, CT 06520-8020

Running head: TUG cleavage regulates GLUT4 translocation

Address correspondence to: Jonathan S. Bogan, Section of Endocrinology and Metabolism, Department of Internal Medicine, Yale University School of Medicine, P.O. Box 208020, New Haven, CT 06520-8020. Tel: 203-785-6319. Fax: 203-785-6462. Email: jonathan.bogan@yale.edu

Background: GLUT4 glucose transporters are trapped and sequestered intracellularly in adipocytes by TUG.

Result: Insulin stimulates TUG cleavage, which separates regions of TUG that bind GLUT4 and Golgi matrix proteins. Cleavage is required for highly insulin-responsive GLUT4 translocation.

Conclusion: TUG proteolysis liberates GLUT4 trapped at the Golgi matrix.

Significance: Endoproteolytic cleavage is a novel biochemical mechanism for insulin action to regulate glucose uptake.

SUMMARY

To promote glucose uptake into fat and muscle cells, insulin causes the translocation of GLUT4 glucose transporters from intracellular vesicles to the cell surface. Previous data support a model in which TUG traps GLUT4-containing vesicles and tethers them intracellularly in unstimulated cells, and in which insulin mobilizes this pool of vesicles by releasing this tether. Here we show that TUG undergoes site-specific endoproteolytic cleavage, which separates a GLUT4-binding, N-terminal region of TUG from a C-terminal region previously suggested to bind an intracellular anchor. Cleavage is accelerated by insulin stimulation in 3T3-L1 adipocytes, and is highly dependent upon adipocyte differentiation. The N-terminal TUG cleavage product has properties of a novel 18 kD ubiquitin-like modifier, which we call TUGUL. The C-terminal product is observed at the expected size of 42 kD, and also as a 54 kD form that is released from membranes into the cytosol. In transfected cells, intact TUG links GLUT4 to PIST, and also binds Golgin-160 through its C-terminal region. PIST is an effector of TC10α, a GTPase previously shown to transmit an insulin signal required for GLUT4 translocation, and we show using RNAi that TC10α is required for TUG proteolytic processing. Finally, we demonstrate that a cleavage-resistant form of TUG does not support highly insulin-responsive GLUT4 translocation or glucose uptake in 3T3-L1 adipocytes. Together with previous results, these data support a model whereby insulin stimulates TUG cleavage to liberate GLUT4 storage vesicles from the Golgi matrix, which promotes GLUT4 translocation to the cell surface and enhances glucose uptake.

To increase glucose uptake into fat and muscle cells, insulin stimulates the translocation of GLUT4 glucose transporters (1-3). In unstimulated cells, GLUT4 is sequestered intracellularly in insulin-responsive “GLUT4 storage vesicles” (GSVs) (4,5). GSVs are formed in a cell type-specific manner, which is differentiation-dependent in cultured 3T3-L1 adipocytes. These vesicles constitute a pool that is mobilized within minutes after insulin addition. Efficient GLUT4 sequestration in GSVs limits the number of GLUT4 transporters that are present at the surface of unstimulated cells, and restricts basal glucose uptake. Insulin is then able to increase plasma membrane GLUT4 abundance severalfold, and to markedly enhance the rate of glucose uptake. GSV mobilization is quantitatively the most important of the trafficking...
steps at which insulin acts to modulate overall GLUT4 distribution. Yet, how GSVs are retained within unstimulated cells, and how they are translocated upon insulin stimulation, is not well understood.

We previously identified TUG as a regulator of GLUT4 trafficking, and proposed that it regulates GSV sequestration and release (6,7). In 3T3-L1 adipocytes, TUG is a 60 kD protein present in the cytosol and on membranes, which binds and sequesters GLUT4 intracellularly in the absence of insulin. To translocate GLUT4, insulin stimulates the release of GLUT4 from TUG (6,8). Release occurs prior to significant GLUT4 movement out of a light microsome (LM) fraction, which contains GSVs, and the number of released proteins determines the number of GLUT4 molecules that are translocated to the cell surface within 3-6 min. after insulin addition (1,6,9). Depletion of TUG using RNAi mimics much of the effect of insulin to stimulate GLUT4 translocation and glucose uptake (7). Like acute insulin stimulation, TUG depletion mobilizes ~60 nm vesicles to the cell surface; these vesicles carry GSV cargos and fuse directly with the plasma membrane (10). This vesicle size is characteristic of GSVs and distinct from other exocytic vesicles (10,11). During ongoing (≥15 min.) insulin exposure, GSV cargos recycle in ~150 nm vesicles characteristic of endosomes, and bypass a TUG-regulated membrane trafficking step. Thus, GLUT4 participates in two different exocytic pathways, which are active at distinct times after insulin addition in 3T3-L1 adipocytes. The data support the idea that the initially translocated vesicles are GSVs that are regulated by TUG, whereas subsequent GLUT4 exocytosis bypasses this GSV sequestration compartment and returns directly to the plasma membrane from endosomes.

The notion that insulin stimulates the release of sequestered GSVs to the cell surface, and that GLUT4 then participates in an endosomal recycling pathway, is consistent with previous data suggesting a “quantal release” mechanism for GLUT4 mobilization (12,13). According to this model, discrete packets of GLUT4 molecules are liberated from a sequestered storage compartment into the recycling pool. Yet, the mechanism by which GLUT4 is released from TUG is not understood. Here we show that TUG is a substrate for site-specific endoproteolytic cleavage, which is required to translocate GLUT4. Our data support the concept that TUG proteolysis is a novel enzymatic activity by which insulin mobilizes GSVs to stimulate glucose uptake.

**EXPERIMENTAL PROCEDURES**

**Materials** – 3T3-L1 and 293T cells were cultured as described (7). Retroviruses were used to express a TUG shRNA and/or various cDNAs in 3T3-L1 adipocytes as described (7). TUG C-terminus and GLUT4 antisera were described previously (6,7). Antisera to the TUG N-terminus were raised in rabbits using a synthetic peptide (residues 1-26 of 60 kD TUG) conjugated to KLH, and were affinity purified using a shorter peptide (residues 10-26). Antiseras to PIST were purchased from Abcam (Cambridge, MA) and were also raised using a 13-residue peptide corresponding to the C terminus of murine PIST. Peptide syntheses were done at the W. M. Keck Biotechnology facility at Yale. Conjugation to KLH, immunizations, and antisera collection were done by Covance, Inc. (Denver, PA) and OpenBiosystems (Huntsville, AL). Anti-myec (9E10) and HA (HA.11) antibodies were from Roche and Covance. Other antibodies (suppliers) were directed to: Hsc70 (Stressgen Bioreagents), insulin receptor β-chain (Upstate Biotechnology), phosphotyrosine (P-Tyr 100, Cell Signaling Technology), GLUT1 (Chemicon), syntaxins -6 and -16 (Synaptic Systems, GmbH), Vti1a (BD Transduction Labs), VAMP4 and VAMP3 (Abcam), transferrin receptor (Pharmingen and Santa Cruz Biotechnology), GFP (Clontech and Invitrogen), and TC10α (Sigma). An antibody to Golgin-160 was kindly provided by Dr. Carolyn Machamer (Johns Hopkins Univ., Baltimore MD). MG-132 and lactacystin were from Sigma and Calbiochem, respectively, and were used at 10 µM unless otherwise indicated. 293T cells were transfected using Fugene6 (Roche) or Lipofectamine 2000 (Invitrogen). Retroviruses containing a TUG shRNA and shRNA-resistant, wildtype TUG were described previously (7). Flag-tagged TUGUL, TUGULΔGG, and TUGUL K134R were made using PCR, cloned in pcDNA3.1-TOPO.
TUG cleavage regulates GLUT4 translocation

(Invitrogen), and sequenced. An HA-tagged ubiquitin plasmid was a kind gift of Drs. Hamid Band and Dirk Bohmann. Coding sequences for TUG GGAA, S165M, and K380R were made by overlap PCR using the shRNA-resistant cDNA template. GLUT4 containing 7 myc tags in the first exofacial loop was constructed by using PCR to insert a stop codon and eliminate the GFP from a previously described reporter (9). Sequence encoding PIST was amplified by PCR from murine skeletal muscle cDNA (Clontech), and cloned in pcDNA3.1 TOPO (Invitrogen). The neuronal splice variant (‘nPIST’) was obtained (14). An HA epitope tag was added at the N terminus using PCR, and the clone was expressed using the pBICD4 retrovirus vector (6,15). An expression plasmid encoding GFP-tagged Golgin-160 was a kind gift from Dr. Carolyn Machamer (Johns Hopkins Univ.). All constructs were verified by sequencing. For expression of full length TUG or TUG UBX-Cter containing IgG binding domains from Protein A, the pRAV-flag vector was used (16) and was a kind gift from Dr. Xuedong Liu (Univ. of Colorado). These plasmids were transfected in 293T cells and purifications were done as described (16). For retroviral expression in 3T3-L1 adipocytes, cDNAs were cloned in the pBICD2 or pBICD4 vectors (6,15). Retrovirus packaging, transduction, and selection of infected cells were done as described (9,15,17).

Recombinant proteins and binding experiments – GST-TUG, GST-TUG-UBX-Cter and GST alone were cloned and expressed as described (7). In vitro translation of PIST was done in the presence of [35S]methionine, and binding experiments were carried out as described (7). For pulldown experiments using 3T3-L1 adipocyte lysates, cells were lysed in TNET buffer (1% Triton X-100, 150 mM NaCl, 20 mM Tris [pH 8.0], 2 mM EDTA) and incubated with immobilized GST-TUG or GST. Bound proteins were eluted in SDS-PAGE sample buffer, separated by SDS-PAGE, and visualized by GelCode Coomassie staining (Pierce).

RNA interference – RNAi of TC10α employed synthetic siRNAs purchased from Thermo Scientific Dharmacon. The target sequences were: TC10-1, GATAGGTGCATGCTGCTAT; TC10-2, CTATGATCGTCTGAGGCCT; Luciferase, CGTACGCGGAATACTTCGA. siRNA duplexes were transfected into 3T3-L1 adipocytes by electroporation using siPORT buffer (Ambion) as described (7). Retrovirus expression of a short hairpin RNA (shRNA) to deplete TUG in 3T3-L1 adipocytes was described previously (7).

Immunoblotting and immunoprecipitation – Denaturing lysis was done at >80° C in 1% SDS, 50 mM Tris pH 8.0, 150 mM NaCl, 2 mM EDTA, 20 mM iodoacetamide (Sigma) and Complete tablets (Roche, 1 tab/20 ml). Protein concentrations were assayed in triplicate using micro-BCA (Pierce) or EZQ (Invitrogen) kits and a Perkin Elmer Victor3 plate reader. SDS-PAGE and immunoblotting were done as described (9).

To immunoprecipitate proteins after denaturing lysis, DNA was sheared using a needle or by sonication, debris was pelleted, and lysates were diluted tenfold using PBS, 1% NP-40, 0.5% sodium deoxycholate. For lysates of 293 cells transfected with flag-TUGUL, a flag M2 affinity matrix (Covance) was used overnight at 4° C. After washing, bound proteins were eluted using sample buffer or an excess of flag peptide. Eluted proteins were analyzed by SDS-PAGE and immunoblotting. Sequence alignments were done using ClustalX, and were further adjusted manually (18).

Pulse-chase experiments – The protocol was adapted from (19). 3T3-L1 adipocytes overexpressing TUG were cultured in 10 cm dishes, starved overnight, then placed in DMEM lacking Cys and Met for 1 h. Cells were labeled for 10 min. at 37° C using 0.7 mCi per dish of [35S]-Express protein labeling mix, a mixture of radiolabelled Cys and Met (DuPont/New England Nuclear). Cells were washed, then chased in DMEM containing nonradioactive Cys and Met and 500 µM cycloheximide. Pairs of plates were chased with or without insulin as described (9). At intervals, cells were lysed in boiling 1% SDS as above. Lysates were passed through a 22 g needle, then centrifuged to pellet insoluble debris. Supernatants were diluted tenfold using TNET (20 mM Tris pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100). Immunoprecipitations were done overnight using 75 µl crude antisera per sample.

Downloaded from http://www.jbc.org/ by guest on October 5, 2017
Eluted proteins were analyzed by SDS-PAGE, and gels were dried and exposed using a Storm phosphorimager (GE Life Sciences).

Subcellular fractionation – PM, LM, and HM fractions were isolated as described (7,9). Equal protein amounts in each fraction were immunoblotted. To separate total membranes from cytosol, each 10 cm plate of 3T3-L1 adipocytes was homogenized in 1 ml of an ice-cold TES buffer (250 mM sucrose, 10 mM Tris, pH 7.4, 0.5 mM EDTA, and 20 mM iodoacetamide) using a Dounce-type tissue grinder. Homogenates were centrifuged for 30 min. at 2°C in a TLA120.2 rotor (Beckman) at 100,000 rpm to pellet membranes. The pellet was resuspended in SDS-PAGE sample buffer, EZQ protein assays were done on both the supernatant (cytosol) and pellet (total membranes), and equal amounts of protein were analyzed by immunoblotting.

Confocal microscopy – 3T3-L1 adipocytes were grown on coverslips, insulin stimulated, fixed, and permeabilized as described (19). To visualize GLUT4, cells stably expressing a GFP-tagged GLUT4 reporter protein were used (9). Syntaxin-6 staining was detected using an AlexaFluor594-conjugated goat anti-Rabbit IgG secondary antibody. Images were acquired on an Axiovert 100M microscope equipped with a LSM510 scanning unit and 63x 1.3 NA plan Apochromat objective (Zeiss) as described (7). Postprocessing was done at 12-bit pixel depth and linear gamma using ImageJ and Adobe Photoshop.

Glucose uptake – 2-deoxyglucose uptake assays were done as described (7). To control for nonspecific uptake, 20 μM Cytochalasin B or 200μM zHFFe were used (20). Similar results were obtained using each of these reagents. Assays were done in triplicate, and data are plotted as mean ± S.E.M. Significance was assessed by a two-tailed Student’s t-test.

Translocation of newly synthesized GLUT4 – The protocol was adapted from (21). Control 3T3-L1 adipocytes, cells stably expressing a TUG shRNA, or cells with the shRNA together with shRNA-resistant forms of TUG were electroporated using pB-GLUT4-7myc-GFP plasmid (6,9). Cells were replated on coverslips after electroporation. Twenty hours after electroporation, staining of surface exposed myc epitope tag was done essentially as described (9,22). Cells were washed three times with warm DMEM and incubated in DMEM for 4 h. Insulin (160 nM) was added for 15 min at 37°C to the “insulin” cells, while “basal” cells were kept in DMEM. Cells were washed three times with PBS, fixed with 2% paraformaldehyde in PBS for 5 min. at room temperature, washed three times with PBS, stained with mouse anti-myc (9E10) for 1 h at RT, washed three times with PBS, stained with AlexaFluor 546 goat anti-mouse IgG for 35 min at RT, washed three times with PBS, and mounted using ProLong Gold antifade mounting reagent (Invitrogen).

Images were acquired using a Zeiss plan-neofluar 40x/1.3 N.A. oil objective on a Zeiss Axiovert 200M widefield microscope driven by AxioVision imaging software (Carl Zeiss, Inc.). AlexaFluor 546 was imaged using a rhodamine filter set and GFP using a FITC filter set. Identical image acquisition settings were used for all the images. Image analysis was performed using MetaMorph software. Image background was determined as previously described (23). This background value was then subtracted from every pixel in the field. The images were then quantified by manually outlining each cell, and by taking the mean fluorescence intensities associated with the cell. The ratio of Alexa 546 fluorescence to GFP fluorescence was calculated and averaged over many cells (at least 16 for basal cells, and at least 27 for insulin-stimulated cells). This ratio is a measure of surface Myc-GLUT4-GFP normalized for the total construct expressed (9,22).

Flow cytometry – Cells infected with retroviruses carrying CD2 or GFP markers were identified using Becton-Dickenson FACScan and FACS Calibur analyzers (6,7,9). Measurement of GLUT4 trafficking was performed as described (6,9). Stable populations of infected cells were purified by flow sorting on a FACS Vantage system at the Yale Cell Sorter Facility.

Results
Ubiquitin and ubiquitin-like modifiers (collectively termed Ubls) are produced by
endoproteolytic cleavage of precursor proteins (24). We hypothesized that TUG is a novel such precursor protein. Previous work had identified two ubiquitin-like regions in TUG, including N-terminal (residues 10-83) and UBX (residues 377-462) domains (6,25). Based on an initial immunoblot suggesting that TUG is cleaved, we considered that TUG contains a third ubiquitin-like domain (residues 92-164) and that it may be cleaved at the 164-165 bond (Figure 1A). Such a cleavage event would separate an N-terminal region that binds GLUT4 from a C-terminal region that was previously proposed to bind an intracellular anchoring site (6,7).

Ubl precursors are typically cleaved after a diglycine motif, which is present in TUG (see below). The mature Ubl (i.e. the N-terminal product) is then covalently attached through its C-terminal glycine residue to protein or lipid substrates. We hypothesized that TUG endoproteolytic cleavage gives rise to a new Ubl, which we call TUGUL (for “TUG Ubiqutin-Like”). TUGUL corresponds to residues 1-164 of intact TUG and is predicted to contain tandem β-grasp folds, similar to two known Ubls, ISG-15 and FAT10 (24). We refer to these domains as “UBL1” and “UBL2” in Figure 1A. The UBX domain of TUG can then also be called “UBL3.” Based on previous evidence supporting the idea that TUG regulates GSVs, we hypothesized that TUG cleavage may be required to translocate these vesicles.

To test if TUGUL is produced from endogenous TUG in 3T3-L1 adipocytes, we raised an antibody to the TUG N-terminus. This antibody detected a 130 kD protein, as well as intact, 60 kD TUG on immunoblots of whole cell lysates (Figure 1B). Both proteins were depleted by TUG shRNA and rescued by shRNA-resistant TUG, supporting the concept that the 130 kD protein is a TUGUL-modified (i.e. “tugulated”) substrate, as well as supporting the specificity of the antibody. A previously characterized antibody to the TUG C-terminus detected intact, 60 kD TUG, but not the 130 kD band. The C-terminus antibody also detected bands at 54 kD and 42 kD, which were not detected by the N-terminus antibody. The predicted mass of the proposed TUG C-terminal product (containing residues 165-550) is 42 kD. As can be seen in Figure 1B, this band was also depleted by the TUG shRNA, and rescued by shRNA-resistant, wildtype TUG (see the darker exposure of C-terminus immunoblot). As described below, the 54 kD band may also be derived from intact TUG, and in Figure 1B its abundance was slightly reduced by the shRNA and markedly increased by shRNA-resistant TUG. These observations support the idea that endogenous TUG is cleaved in 3T3-L1 adipocytes and that cleavage produces TUGUL, which is then used for covalent, ubiquitin-like protein modification.

As shown in Figure 2A, the primary sequence of TUG UBL2 has limited similarity with ubiquitin, SUMO, and other Ubls, which is not unusual for ubiquitin-like family members (24). This region was nonetheless suggested to comprise a UBX or UBX-like domain (26,27). Importantly, TUG UBL2 terminates with a diglycine motif, defining a potential site for proteolytic cleavage by a deubiquitinating enzyme (DUB) family member. Additionally, a lysine residue (K134) that may be analogous to ubiquitin K48, a prototypical site of polyubiquitin chain formation, is present in UBL2. As shown in Figure 2B, the C terminal sequence of TUGUL is most closely related to those of ubiquitin, ISG15, and NEDD8, but it shares with SUMO1 and SUMO2/3 a threonine residue immediately preceding the terminal diglycine sequence.

To test whether mature TUGUL, if produced, would be able to modify a target protein, we transfected 293T cells. As shown in Figure 2C, flag-tagged TUGUL was present not only at 18 kD, which corresponds to the predicted size of this protein, but also as a 26 kD form. The 26 kD form was resistant to heat and ionic detergent, and was not affected by mutation of K134R. Rather, the 26 kD TUGUL-containing product required the terminal diglycine sequence of TUGUL, which is characteristic of ubiquitin-like attachment (28). Additionally, the abundance of this putative tugulated product was increased by cotransfection of GLUT4, which binds both TUGUL (7) and Ubc9 (29), a SUMO-conjugating enzyme. We used mass spectrometry of tryptic peptides to identify the putative 26 kD TUGUL-conjugated protein, and observed peptides derived from
ubiquitin. Therefore, we cotransfected HA-tagged ubiquitin together with flag-tagged TUGUL. As shown in Figure 2D, these proteins were coimmunoprecipitated after denaturing lysis, supporting the idea that they are covalently attached to each other. The terminal diglycine of TUGUL was required for this association, suggesting that the 26 kD band is tugulated ubiquitin rather than ubiquitylated TUGUL. Ubiquitin is likely not the physiological substrate of TUGUL attachment, since the putative tugulated conjugate in 3T3-L1 adipocytes totals 130 kD. Nonetheless, the data support the hypothesis that TUGUL is able to function as a ubiquitin-like protein modifier, and that it may do so if it is produced physiologically by TUG cleavage.

We next tested if insulin stimulates TUG cleavage in 3T3-L1 adipocytes. We predicted that cleavage generates a C-terminal product beginning with Ser-165. This residue will be unacetylated, and it is predicted to cause rapid proteasomal degradation of the product according to an N-end rule (30,31). We therefore treated cells briefly with or without a proteasome inhibitor, MG-132, then stimulated with insulin. Immunoblots showed that insulin stimulated the generation of the 42 kD C-terminal product, and MG-132 increased the abundance of this protein, as predicted (Figure 3A). The abundance of intact TUG was not markedly changed by insulin or MG-132. In control experiments, MG-132 did not affect GLUT4 translocation (not shown). These data support the notion that insulin accelerates TUG cleavage, and further imply that only ~10% of total cellular TUG is cleaved in 3T3-L1 adipocytes. As noted below, this is consistent with a model in which cleavage of one or a few TUG proteins serves to liberate each GSV.

Unexpectedly, the initial band that appeared after insulin addition, using the TUG C-terminus antibody, was 54 kD, not 42 kD (Figure 3A). As described below, we believe that this 54 kD protein is a modified form of the 42 kD product. The 54 kD and 130 kD bands were produced simultaneously and were detected exclusively by the TUG C- and N-terminus antibodies, respectively. This finding suggests that the 130 kD and 54 kD proteins are generated as two products of a single biochemical process, which is accelerated by insulin and includes TUG cleavage.

To further test if the 130 kD, 54 kD, and 42 kD proteins all derive from TUG, we used control and shRNA-containing 3T3-L1 adipocytes. Figure 3B shows that these proteins appeared after insulin treatment of control cells, and not shRNA cells. As was shown in Figure 1B, shRNA-resistant TUG rescued the 130 kD protein and increased the abundance of the 54 kD and 42 kD bands. Densitometry of several immunoblots revealed that >97% depletion of intact, 60 kD TUG was required to deplete the 130 kD protein. Together, the data support the idea that insulin stimulates the production of a single, 130 kD TUGUL-modified protein, in addition to 54 kD and 42 kD proteins containing a TUG C-terminal fragment.

To show directly that intact TUG is converted to a C-terminal cleavage product, we performed pulse-chase experiments. Newly synthesized proteins in 3T3-L1 adipocytes overexpressing intact TUG were pulse labeled for 10 min. using [35S] -Cys and -Met. Cells were chased using non-radioactive amino acids and cycloheximide, and pairs of samples chased in the absence or presence of insulin were lysed at intervals using denaturing conditions. Immunoprecipitations were done using an antibody to the TUG C-terminus, and eluates were analyzed by SDS-PAGE and phosphorimaging. Figure 3C shows that intact 60 kD TUG was isolated from cells chased for 0 or 5 min., and in cells chased for 10 min. in the absence of insulin. At later times, intact TUG was not present and the 42 kD C-terminal product was observed. The effect of insulin to accelerate the conversion of 60 kD TUG to the 42 kD product was particularly evident at 10 min. into the chase period. At later times, the 42 kD product was always more abundant in insulin-treated cells than in unstimulated cells from the same timepoint. A ~62 kD band also appeared in cells chased for 10 min. in the presence of insulin, and this band also was more abundant in cells chased in insulin than in unstimulated cells from the same timepoint (Figure 3C, asterisk). Coomassie staining revealed abundant IgG, used for the immunoprecipitation, immediately below this band (Figure 3C, bracket). Therefore this band may be the 54 kD product noted in Figures 1B, 3A and 3B, which migrates
above the IgG in Figure 3C. Importantly, intact 60 kD TUG was converted to the predicted 42 kD C-terminal product, and this conversion was accelerated, at least to some degree, by insulin.

To define the scissile bond as that joining residues 164 and 165, we used forms of TUG containing specific mutations. First, we changed the diglycine sequence to dialanine to create TUG GGAA, a form predicted to be cleavage-resistant (32). Second, we changed Ser-165 to Met to create TUG S165M, which may disrupt modification or degradation of the C-terminal product. Finally, we mutated Lys-380 to Arg to create TUG K380R, which may disrupt modification or degradation of the C-terminal product. These proteins were expressed as shRNA-resistant forms in 3T3-L1 adipocytes containing an shRNA to deplete native TUG. Cells were treated with insulin, lysed in denaturing conditions, and immunoblotted to detect C-terminal products.

Figure 3D shows that insulin stimulated the generation of the 54 kD modified product in control 3T3-L1 adipocytes, as best observed on a darker exposure. This 54 kD product was depleted by TUG shRNA and rescued by shRNA-resistant, wildtype TUG (in shRNA+TUG WT cells). In shRNA+TUG GGAA cells, the 54 kD band was not produced, supporting the prediction that TUG GGAA is cleavage-resistant. In shRNA+TUG S165M cells, the 42 kD unmodified C-terminal product accumulated as predicted, and was observed even in unstimulated cells. The S165M mutation also stabilized the 54 kD modified product, as well as other forms that may reflect alternative degradation pathways. In shRNA+TUG K380R cells, the 54 kD product accumulated, suggesting that K380 is a site that is used for ubiquitin-mediated degradation. These data support the idea that insulin stimulates TUG cleavage between residues 164 and 165.

The degree to which insulin stimulated the production of TUG cleavage products was variable in 3T3-L1 adipocytes. In some experiments, the effect of insulin was minimal or absent, because TUG derivatives were observed in unstimulated 3T3-L1 cells. In other experiments, the effect of insulin to increase the abundance of TUG products was more marked. Together with data below identifying an insulin signal required for TUG proteolytic processing, we conclude that insulin stimulates cleavage. The variability in insulin’s effect may result from post-lysis proteolysis, which is typical of Ubls and could increase the abundance of products observed in unstimulated cells (33). We used heat and ionic detergent, as well as iodoacetamide, to try to prevent such an artifact. It is also likely that TUG is cleaved at some rate in unstimulated 3T3-L1 adipocytes, and that insulin accelerates this rate rather than acting as a binary switch, as described further below. Finally, insulin’s ability to stimulate GLUT4 translocation is cell type-specific and, in 3T3-L1 cells, differentiation-dependent. Thus, we considered that the degree to which insulin can stimulate TUG cleavage may also be affected by the degree of adipocyte differentiation.

To test directly the idea that TUG proteolysis occurs in a differentiation-dependent manner, we performed immunoblots of non-adipose 293T cells, and of 3T3-L1 cells at various stages of differentiation. As shown in Figure 4A, the TUG C-terminus antibody readily detected the 42 and 54 kD products in 3T3-L1 adipocytes, but these products were barely discernable in 293T cells. Figure 4B quantifies the abundance of the major 54 kD product, relative to the intact 60 kD TUG protein, in various cells. The 54 kD product was present at only ~3% of the abundance of intact TUG in 293T cells and in confluent, undifferentiated 3T3-L1 preadipocytes. The abundance of this product was only ~7% of that of intact TUG in partially differentiated 3T3-L1 cells. At this stage of differentiation (Day 5), GLUT4 is just beginning to be expressed, and the translocation mechanism is present but perhaps not fully developed. In fully differentiated 3T3-L1 adipocytes (Day 10), the 54 kD product was present at >20% of the abundance of intact TUG. As shown below, the number of TUG molecules that are cleaved corresponds well with the number of GSVs that are present in each cell. The results support the idea that TUG proteolytic processing is cell type-specific, and that in 3T3-L1 cells it is highly dependent upon adipocyte differentiation.

**Processing of TUG on membranes containing GSVs** – To study where TUG processing occurs, we isolated membrane and cytosol fractions from
TUG cleavage regulates GLUT4 translocation

3T3-L1 adipocytes. As previously noted, TUG is present in both of these fractions, and insulin often causes no change or a slight increase in the abundance of membrane-associated TUG, which is in a LM fraction (6,7). In Figure 5A, insulin caused an increase in the abundance of intact TUG on membranes. The 42 kD unmodified C-terminal product was generated exclusively on membranes. The 54 kD modified C-terminal product was observed in both fractions, and was more abundant in cytosol in several experiments. Like the 42 kD product, the 130 kD putative TUGUL-modified protein was produced on membranes. The 130 kD product was more abundant than intact TUG, which together with other data suggests it may be more stable. These data support the idea that TUG proteolytic processing and TUGUL modification occurs on membranes.

Conversion of the 42 kD C-terminal product to the 54 kD form likely occurs after cleavage of intact TUG. This is because 1) the 54 kD protein is present in a different location than the 42 kD and 130 kD products, and 2) cleavage-resistant TUG does not accumulate as a ~72 kD form, which would be predicted if modification preceded cleavage. Because the SUMO-conjugating enzyme, Ubc9, binds and regulates GLUT4 (29,34), we tested if the 54 kD form is a sumoylated form of the 42 kD product. We were not able to obtain evidence that the 54 kD protein contains SUMO, and identification of the modification will require further work. Even so, one possibility is that the modification may be involved in removing the unmodified C-terminal cleavage product from an intracellular anchoring site, as discussed below.

To further examine where TUG processing takes place, we isolated plasma membrane (PM), light microsome (LM), and heavy microsome (HM) fractions. We used control 3T3-L1 adipocytes and cells containing a truncated form of TUG, UBX-Cter (residues 377-550), which acts in a dominant negative manner to block intracellular GLUT4 sequestration in cells not treated with insulin (6,7). In control cells, insulin redistributed GLUT4 out of the LM fraction, which contains GSVs, and to the PM (Figure 5B). TUG UBX-Cter disrupted this response by inhibiting the basal, intracellular retention of GLUT4, as observed previously (7).

Intact TUG was detected in the LM fraction by both the N- and C-terminus antibodies, and was redistributed slightly to the PM by UBX-Cter. The 130 kD TUGUL-modified protein was detected by the N-terminus antibody in the LM and PM fractions of control cells, and this protein was not present in cells containing TUG UBX-Cter. This band was also not detected by the C-terminus antibody, consistent with data shown above and with the idea that it contains only the N-terminal cleavage product. Because ubiquitin-like processing may occur in non-denaturing conditions such as cell homogenates, the data in Figure 5B do not address whether insulin affects the location or abundance of the TUGUL-modified protein. The UBX-Cter fragment itself was not visible on the TUG C-terminus immunoblot. This fragment is present at low abundance relative to intact TUG, and it may also be degraded in cell homogenates. As discussed further below, if intact TUG is a substrate and not an enzyme, then UBX-Cter may act irreversibly (in modified form) to inhibit GLUT4 retention. In summary, the TUGUL-modified protein is produced on membranes that contain GSVs. TUG UBX-Cter not only inhibits GLUT4 retention, but also blocks the generation of the TUGUL-modified protein on these membranes.

Previous data implicate a SNARE complex containing syntaxin-6, syntaxin-16, Vti1a, and VAMP4 (or VAMP3) in trafficking of GSVs at the trans-Golgi network (TGN) (35-39). Among these proteins, syntaxin-6 was dramatically redistributed to PM by dominant negative TUG UBX-Cter (Figure 5B). The syntaxin-6 interacting protein, PIST, which is discussed further below, was also present in the LM fraction, and was slightly dispersed by TUG UBX-Cter. Of note, syntaxin-6 was identified in GSV-enriched membranes by mass spectrometry, and is abundant in the TGN and in endosomes (40-42). Confocal microscopy confirmed that syntaxin-6 is redistributed to the cell surface by TUG UBX-Cter (Figure 6A). Similar results were obtained by subcellular fractionation of shRNA cells, in which syntaxin-6 was redistributed to PM in unstimulated cells (Figure 6B). The data support the idea that TUG regulates GSVs that arise from syntaxin-6 – containing membranes, possibly the TGN or endosomes.
TUG cleavage regulates GLUT4 translocation

TUG cleavage liberates GLUT4 from the Golgi matrix and requires TC10α – The observation that TUG disruption redistributed syntaxin-6 prompted us to test if proteins that associate with syntaxin-6 may bind and regulate TUG and GLUT4. An excellent candidate was PIST (also called FIG, GOPC, and CAL), which binds syntaxin-6 and controls the PM targeting of CFTR proteins, frizzled isoforms, CIC3-B, AMPA-type glutamate receptors, and other receptors (1,14,43-48). PIST is an effector of the TC10α GTPase (49), which mediates insulin-stimulated GLUT4 translocation (50) and also regulates the cell surface targeting of CFTR proteins and AMPA receptors (51-53).

Figure 7A shows that PIST can be coimmunoprecipitated in a complex together with TUG and GLUT4. PIST was purified with GLUT4 only when TUG was coexpressed, supporting the concept that these proteins participate in a linear arrangement, with TUG interposed between GLUT4 and PIST. We used recombinant proteins to show that TUG and PIST can bind each other directly (Figure 7B). Endogenous PIST colocalized with TUG and with insulin-responsive GLUT4 in LM fractions, and was not translocated by insulin, as noted above (Figure 5B). By confocal microscopy, HA-tagged PIST colocalized with perinuclear GLUT4 in 3T3-L1 adipocytes, and was not translocated to the cell surface by insulin (Figure 7C). These data support the idea that GLUT4, TUG, and PIST can form a complex, and that this complex may regulate GSVs.

PIST binds the Golgi matrix protein Golgin-160, which like TUG is required for the intracellular retention of GLUT4 in unstimulated cells (54,55). Accordingly, we tested if TUG binds Golgin-160. Figure 7D shows that TUG and Golgin-160 were coprecipitated from transfected cells. Moreover, a truncated fragment of TUG was able to purify Golgin-160, which maps the interaction to the TUG C-terminal region (residues 377-550). This UBX-Cter fragment functions as a dominant negative protein, as noted above, and it was hypothesized to bind an anchoring site but not GLUT4 or other GSV components. By excluding endogenous TUG from this site, it blocks the ability of intact TUG to retain GLUT4 within unstimulated cells. Therefore, the data implicate Golgin-160 and PIST as components of this intracellular anchoring site. Together, the data support a model whereby cleavage separates N- and C-terminal regions of TUG that bind GSVs and the Golgi matrix, respectively.

As noted above, TC10α is required to transmit an insulin signal for GLUT4 translocation (50), and we considered that TC10α may signal through PIST to promote TUG cleavage. To test the hypothesis that TUG proteolytic processing requires TC10α, we transfected 3T3-L1 adipocytes with siRNAs. Figure 7E shows that in cells in which TC10α was depleted, basal and insulin-stimulated production of the 54 kD TUG C terminal product was markedly reduced. By contrast, in control 3T3-L1 adipocytes that were mock transfected, or transfected with an irrelevant siRNA, the 54 kD product was observed, and was increased after insulin stimulation. These data indicate that TC10α is required for basal as well as insulin-stimulated TUG processing. Additionally, the data highlight the physiologic significance in 3T3-L1 adipocytes of interactions of TUG with PIST and Golgin-160. Together with previous results, we conclude that insulin signaling through TC10α is required to accelerate TUG proteolytic processing.

If TUG traps GSVs at the Golgi matrix, and if TUG cleavage liberates GSVs for exocytic translocation, then the number of TUG proteins that are cleaved should relate stoichiometrically to the number of insulin-responsive GSVs in each cell. Previous data show that there are about 300,000 copies of GLUT4 per 3T3-L1 adipocyte (56). Of this number, about 30-40% is in GSVs in unstimulated cells, and the remainder is in endosomes, GSV donor membranes, and the plasma membrane (1). Thus in a typical 3T3-L1 adipocyte, about 100,000 molecules of GLUT4 are present in GSVs in the absence of insulin. Other work has shown that there are about 5-6 molecules of GLUT4 in each GSV (57). Therefore, there are approximately 20,000 GSVs in each unstimulated 3T3-L1 adipocyte.

To determine if the number of TUG molecules that are present in each 3T3-L1 adipocyte, we used a recombinant TUG protein. Figure 8A compares
coomassie-stained GST-TUG-UBX-Cter and an albumin standard. Ten microliters of a 1:20 dilution of the recombinant TUG stock contained 20 ng of this protein, or about 2.5x10^11 molecules (based on the molecular weight of GST-TUG-UBX-Cter, which is 47 kD). Figure 8B presents immunoblots of recombinant GST-TUG-UBX-Cter and 3T3-L1 adipocyte whole cell lysates, which were done using the antibody directed to the TUG C terminus. The lysates contained material from 6x10^4 cells, and the number of intact, 60 kD TUG proteins that were present was similar to that in 1 ng of the recombinant GST-TUG-UBX-Cter sample, or about 1.25x10^10 molecules. Therefore, each 3T3-L1 adipocyte contains approximately 200,000 TUG proteins.

If ~10% of the intact TUG molecules are cleaved in response to insulin (Figure 3), then about 20,000 TUG molecules undergo insulin-stimulated proteolysis in each 3T3-L1 adipocyte. This number corresponds very well to the number of GSVs that are present in each 3T3-L1 adipocyte, which was also calculated at ~20,000, as noted above. These calculations are approximate, but they nonetheless support the idea that only one molecule of TUG (or at most a few molecules) is involved in “tethering” each insulin-responsive GSV at the Golgi matrix in unstimulated 3T3-L1 adipocytes. The data further support the idea that the amount of TUG cleavage we observe could reasonably be expected to liberate the insulin-responsive pool of GSVs for translocation to the cell surface.

**Highly insulin-responsive GLUT4 translocation requires TUG cleavage** – To test directly if TUG cleavage is required to translocate GLUT4, we used several approaches. Initially, we used differential centrifugation to isolate PM, LM, and HM fractions, as previously, and we immunoblotted endogenous GLUT4 in these fractions (7). In control 3T3-L1 adipocytes, insulin stimulated the translocation of GLUT4 out of the LM fraction and to the PM fraction (Figure 9A). This effect was disrupted in shRNA cells and rescued in shRNA+TUG WT cells. In shRNA+TUG GGAA cells, containing cleavage-resistant TUG, GLUT4 responded poorly to insulin. GLUT4 was more abundant in the basal PM fraction, and insulin caused only slight additional movement out of the LM and to the PM fraction. In shRNA+TUG S165M cells, GLUT4 movement was similar to that in shRNA+TUG WT cells, suggesting that rapid degradation of the C-terminal product is not required for acute insulin action. We conclude that TUG cleavage is required for highly insulin-responsive GLUT4 targeting.

We next tested if TUG cleavage is required for insulin to regulate glucose uptake. Figure 9B shows that, similar to previous data, shRNA-mediated TUG depletion enhanced basal glucose transport (7). Insulin caused a twofold further increase, which may be due to TUG-independent fusion of vesicles containing GLUT4 at the plasma membrane, or to effects of insulin on GLUT4 and GLUT1 in endosomes (10). Effects of the shRNA were rescued by shRNA-resistant, wildtype TUG. Cleavage-resistant TUG GGAA did not fully rescue the effect of the shRNA in either basal or insulin-stimulated conditions. Basal glucose uptake remained somewhat increased, but not to the level observed in the shRNA cells, consistent with the fractionation data (Figure 9A). Insulin-stimulated glucose uptake was also increased, and was also less than that observed in the shRNA cells. Because of the increased basal uptake, insulin stimulated only a twofold further increase, which is not typical of highly insulin-responsive glucose uptake. This is similar to the approximately two-fold increase in PM GLUT4 we observed by fractionation of shRNA+TUG GGAA cells. Interpretation of both the fractionation and glucose uptake data is informed by our previous observation that GLUT4 participates in two distinct exocytic pathways, only one of which is regulated by TUG (10). When flux through the TUG-regulated pathway is inhibited, by cleavage-resistant, mutated TUG, GLUT4 is still able to cycle in endosomes. Thus, impaired trapping of endocytosed TUG in GSVs may be predicted to result in increased basal glucose uptake, and a diminished (but not absent) effect of insulin stimulation. The data are consistent with this scenario. We conclude that TUG cleavage is required for highly insulin-responsive glucose uptake.

To test more directly if cleavage-resistant TUG blocks GLUT4 flux through GSVs, we examined
TUG cleavage regulates GLUT4 translocation

newly synthesized GLUT4. In 3T3-L1 adipocytes, transiently transfected GLUT4 enters GSVs directly from the biosynthetic pathway (21,58). Effect on GSVs can then be examined, without interference from GLUT4 recycling through endosomes (10). Thus, we predicted that in shRNA+TUG GGAA cells, basal retention of newly synthesized GLUT4 would be fully rescued, and translocation would be selectively inhibited. Accordingly, we transfected a GLUT4 reporter in cells in which TUG proteins were stably manipulated, and used microscopy to quantify the ratio of surface to total GLUT4 shortly after transfection (9,21). As shown in Figure 9C, we observed insulin-stimulated translocation in control cells, disrupted basal GLUT4 retention in shRNA cells, and rescue of insulin-stimulated translocation in shRNA+TUG WT cells. In shRNA+TUG GGAA cells, the basal intracellular retention of GLUT4 was fully rescued, and there was a dramatic defect in insulin-stimulated translocation, as predicted. The data were quantified in Figure 9D, which shows that both wildtype and cleavage resistant TUG fully rescued the effect of the shRNA to increase basal targeting of GLUT4 to the cell surface. In shRNA+TUG WT cells, insulin-stimulated translocation was slightly greater than that in control cells, consistent with previous data implying that TUG overexpression enlarges the pool of GSVs (6,7). In shRNA+TUG GGAA cells, which contain similarly overexpressed, cleavage-resistant TUG, insulin-stimulated translocation was impaired. We conclude that TUG proteolytic processing is required to mobilize GSVs to the cell surface in 3T3-L1 adipocytes.

DISCUSSION

Glucose uptake is tightly regulated by insulin, which controls the number of GLUT4 glucose transporters present in plasma membranes of fat and muscle cells. GLUT4 is very efficiently sequestered within unstimulated cells. Insulin can then act within minutes to stimulate a large increase in plasma membrane GLUT4 abundance, and does so by causing the acute mobilization of GLUT4 out of intracellular membranes. Insulin acts at multiple sites in GLUT4 trafficking to modulate its overall distribution within cells. The site of regulation that is quantitatively most important is the pool of insulin-responsive storage vesicles, termed GSVs (4). These vesicles are formed in a cell type-specific, differentiation-dependent manner, and are thought to exist as a preformed population within unstimulated cells (59). GLUT4 and only a few other proteins accumulate selectively in GSVs in the absence of insulin (5). These vesicles are mobilized acutely after insulin addition, which accounts for the bulk of insulin action to insert GLUT4 at the cell surface. How GSVs are efficiently sequestered in unstimulated cells, and how they are mobilized by insulin stimulation, is not well understood.

The data presented here support a model in which insulin stimulates TUG cleavage to mobilize GSVs to the cell surface and to augment glucose uptake. The simplest interpretation is that cleavage releases a tethering mechanism that retains the vesicles at the Golgi matrix in unstimulated cells. It is also possible that one or both TUG cleavage products functions as a signal. In particular, TUGUL liberation and covalent attachment to a target protein may activate vesicle translocation to the cell surface. The ideas that cleavage releases a tether, and that TUGUL acts as a signal to promote translocation, are not mutually exclusive. For example, one can envision a model in which TUG cleavage releases GSVs from the Golgi matrix, and TUGUL modification somehow activates kinesin or myosin motor proteins to promote movement of the released GSVs to the cell surface (60-64). Alternatively, the liberated TUGUL might activate proteins that participate in vesicle tethering, docking, or fusion at the plasma membrane (10). Regardless, TUG cleavage is here shown to be a novel biochemical mechanism that is required for fully insulin-responsive GLUT4 translocation and glucose uptake in 3T3-L1 adipocytes.

We previously proposed that TUG is an essential component of a functional tether that binds and sequesters GLUT4 within unstimulated cells (6,7). Data presented here expand upon this model, and implicate site-specific endoproteolytic cleavage of TUG in the release of this sequestration mechanism. Like GLUT4 translocation, TUG cleavage occurs in a differentiation-dependent manner in 3T3-L1 adipocytes. We show that intact TUG can link GLUT4 to Golgi matrix
proteins, PIST and Golgin-160. Cleavage then separates an N-terminal region that binds GLUT4 from a C-terminal region that binds Golgin-160. Cleavage may thus “untether” GSVs from the Golgi matrix. We further show that TC10α is required for the production of TUG cleavage products, consistent with the idea that insulin signaling through TC10α is required to accelerate TUG cleavage and to mobilize GSVs. The number of TUG molecules that are cleaved corresponds approximately to the number of GSVs present in each cell. Finally, we show that cleavage is required for highly insulin-responsive GLUT4 translocation and glucose uptake.

TUG endoproteolysis is the first step in a complicated biochemical processing mechanism that has yet to be fully elucidated. We do not know the identity of the enzyme that mediates TUG cleavage. Our data support the idea that TUG is precursor to a novel ubiquitin-like modifier, TUGUL, and that the cleaving enzyme may therefore be similar to known deubiquitinating enzymes. Mature TUGUL is covalently attached to ubiquitin in transfected 293T cells, suggesting that it would be able to modify a target protein, if produced by cleavage of endogenous TUG. Our data show that endoproteolysis occurs in 3T3-L1 adipocytes, and that the TUG N-terminus is incorporated into a single, ~130 kD protein. This putative tugulated protein remains unidentified at present, despite our efforts to precipitate it using the N terminus antibody or an epitope tag (which disrupted the localization of intact TUG expressed using a retrovirus in 3T3-L1 adipocytes). If the ~130 kD protein contains an 18 kD TUGUL molecule, then the target of TUGUL modification in 3T3-L1 adipocytes is ~110 kD. Several proteins in this size range have been implicated in GLUT4 trafficking (60-63,65,66). The observation that TUGUL binds GLUT4 (7), together with the finding that the 130 kD protein is present in a PM fraction (Figure 5B), suggests that they are the initial products. In addition, cleavage resistant TUG does not accumulate as a ~72 kD form, which might be predicted if the modification preceded cleavage. Thus, one possibility is that the modification is somehow involved in removing the C terminal cleavage product from the anchoring site.

By analogy to known Ubls, our data suggest that activating (E1), conjugating (E2), and ligating (E3) enzymes may mediate TUGUL attachment in 3T3-L1 adipocytes. Ubc9 is well described as a SUMO E2, which binds GLUT4 and controls its targeting and, likely secondarily, its stability (1,29,34,65,67). It is formally possible that Ubc9 could mediate TUGUL conjugation. GLUT4 itself may function as an E3, because it binds TUGUL and may form a scaffold for other enzymes involved in the reaction. Daxx is another protein that binds GLUT4, Ubc9, and SUMO, which has been proposed to scaffold these proteins together with other molecules (63,65). Other GSV cargos, notably IRAP, sortilin, and LRP1, may be more important than GLUT4 itself for the formation and regulation of GSVs (4,5). Understanding if these proteins may contribute to enzymatic activities for TUG proteolysis and TUGUL modification will require further research.

The TUG C terminal product is present as a 54 kD protein, as well as at the predicted mass of 42 kD. The 54 kD form appears to be a covalently modified form of the 42 kD product, because it is observed after cell lysis in denaturing conditions. Although the molecular characterization of this modification will require further work, present data show that the modified form can be stabilized by mutations (e.g. K360R and S165M) within the future TUG C-terminal product. The modification likely occurs after cleavage of the intact TUG protein. The 54 kD form is present in the cytosol, whereas the 130 kD and 42 kD products are both present exclusively in a membrane fraction, suggesting that they are the initial products. In addition, cleavage resistant TUG does not accumulate as a ~72 kD form, which might be predicted if the modification preceded cleavage. Thus, one possibility is that the modification is somehow involved in removing the C terminal cleavage product from the anchoring site.

Whether the TUG C terminal product has an additional function is not known. We recently reported that TUG disassembles the hexameric p97/VCP ATPase into its monomeric subunits (68). The C-terminal half of TUG is highly conserved evolutionarily, and TUG is widely expressed and regulates Golgi dynamics in HeLa cells, possibly through its action on p97. We hypothesize that its function is adapted in a cell type –specific manner to control GLUT4 exocytosis. A TUG fragment corresponding to the
42 kD C terminal product was fully capable of disassembling p97 hexamers in vitro. Although we did not observe a role of the TUG N terminus to modulate this activity, one possibility is that TUG cleavage and p97 oligomeric status are coordinately regulated in adipocytes. Because p97 interacts with clathrin, SNAREs, and other membrane trafficking proteins, its regulation could well control GLUT4 (69-72). For example, the role of TUG to trap GLUT4 intracellularly may require its action to disassemble p97 hexamers and, presumably, to inhibit p97 ATPase activity.

After GLUT4 mobilization, a TUG C terminal product must be removed from the Golgi matrix. p97 is well known to extract proteins from the endoplasmic reticulum (ER) for ER-associated degradation (ERAD), and the putative yeast ortholog of TUG, Ubx4p, has been implicated in this process (73). Possibly, p97 is involved in TUG proteolytic processing and/or in extracting the TUG C-terminal product, given its roles to modulate proteolysis in other instances and to extract cleavage products of the membrane-bound transcription factors, Spt23p/Mga2p and SREBP (74-78). Remarkably, in transfected HeLa cells, the 42 kD TUG C terminal product was targeted to the nucleus, and caused nuclear accumulation of endogenous p97 (68). Thus, it is possible that a C-terminal fragment produced by TUG cleavage in adipocytes is also targeted to the nucleus. Of note, Ubx4p has been implicated in controlling RNA polymerase II turnover (79). Whether TUG functions similarly, and whether TUG cleavage coordinates glucose uptake and gene expression, remains to be seen.

Our data show that TUG interacts with PIST and Golgin-160, implying that it may link GLUT4 to these proteins to sequester GSVs at the Golgi matrix. Other proteins may also bind the TUG C-terminus to mediate intracellular sequestration (6). Golgin-160 was previously shown to be required for full intracellular retention of GLUT4 in unstimulated 3T3-L1 adipocytes (55). A similar function has been described for p115, which binds IRAP and LR1 and is present in a similar location at the cis-Golgi, the ER-Golgi intermediate compartment (ERGIC), and at ER exit sites (ERES) (66,80-83). These data fit well with our observation that TUG is present primarily at the ERGIC, ERES, and cis-Golgi in HeLa cells (68). Together with data supporting the idea that GSVs fuse directly with the plasma membrane (10), we conclude that GSVs may follow an unconventional secretion pathway (3,84).

Our data show that TC10α is required for the production of TUG cleavage products, and indicate that TC10α is coupled through its effector, PIST, directly to TUG and GLUT4. TC10α was previously shown to be required for insulin-stimulated GLUT4 translocation in 3T3-L1 adipocytes (50), and signals through CIP4 and Exo70 to regulate GLUT4 trafficking (85-87). PIST is yet another effector, which may couple TC10α activation directly to the release of GSVs. Of note, TC10α also acts through PIST to regulate CFTR, which follows an unconventional secretion pathway to reach the cell surface (44,51,52,84,88,89). Insulin signaling through TC10α is likely coordinated with signaling through Akt2 to AS160/Tbc1D4 and downstream Rab GTPases (2). By activating the appropriate Rab isoform(s), signaling through AS160 may cause the released GSVs to traffic to the plasma membrane, and not to some other compartment. Conversely, in unstimulated cells, GSVs that are captured by TUG and Golgi matrix proteins may not be entirely static, but may participate in an intracellular cycle into and out of Golgi membranes. Such a cycle could efficiently sequester GLUT4, and would fit well with the function of Golgi matrix proteins to capture vesicles and to direct their fusion at an appropriate cisterna (90). Thus, similar to activated Rab proteins, intact TUG may serve as an adaptor to link particular vesicles – GSVs – to Golgi matrix proteins, and thus to mediate their capture and retention.

We conclude that site-specific proteolysis is required for insulin to regulate glucose uptake in 3T3-L1 adipocytes. Whether this mechanism pertains in muscle is not known. GLUT4 and TUG abundances are highly correlated in skeletal muscles, and insulin stimulates the dissociation of TUG from GLUT4 (8,91). Thus, it seems likely that a similar process is involved in insulin action in muscle. More broadly, our data imply that GLUT4 trafficking shares features with other
molecular systems that employ protein degradation to confer tight control and vectorial directionality. We are not aware of other instances in which insulin acts through site-specific proteolysis. The nearest example may be SREBP1c, which is mobilized into COPII vesicles by insulin, and encounters a protease at the Golgi complex (92,93). As well, mechanisms similar to the one we describe may control other protein-exposing, nonsecretory exocytoses, and may regulate a wide range of physiology (94). Finally, our results may contribute to understanding the pathogenesis of insulin resistance and type 2 diabetes.

REFERENCES


TUG cleavage regulates GLUT4 translocation


FOOTNOTES

*We thank Mark Hochstrasser, Thomas Gniadek, Derek Toomre, Emily Stoops, Whitney Harris, and Hongjie Li for assistance, advice, and comments on the manuscript. We thank Xuedong Liu, Dirk Bohmann, Hamid Band, and Carolyn Machamer for reagents. This work was supported by grants to J.S.B from the NIH (R01DK075772), the American Diabetes Association (1-05-RA-17, 1-12-BS-16), by a Pilot grant from the Yale O'Brien Kidney Center (P30DK079310), and by a Distinguished Young Scholar in Medical Research Award from the W. M. Keck Foundation. B.R.R. was supported by American Heart Association 0815746D, M.H. by NIH K01DK078625, C.M.O. and J.P.B. by NIH T32GM07205, C.M.O. by F30DK086109, and J.P.B. by F30DK093198. This work used the Cell Biology Core of the Yale Diabetes Endocrinology Research Center (P30DK45735), as well as services provided by the W. M. Keck Foundation Biotechnology Resource Laboratory at Yale University.

The abbreviations used are: ER endoplasmic reticulum; ERAD, endoplasmic reticulum associated degradation; ERGIC, endoplasmic reticulum-Golgi intermediate compartment; ERES, endoplasmic reticulum exit sites; GLUT4, Glucose Transporter 4; LM, light microsome; HM, heavy microsome; PM, plasma membrane; TGN, trans-Golgi network; TUG, Tether containing a UBX domain, for GLUT4; TUGUL, TUG Ubiquitin-Like; UBL, ubiquitin-like; UBX, Ubiquitin regulatory X; WB western blot.

FIGURE LEGENDS

Figure 1. Distinct N- and C- terminal TUG derivatives in 3T3-L1 adipocytes. A. TUG is a 550 residue protein containing three ubiquitin-like domains, denoted UBL1, UBL2, and UBL3/UBX. UBL2 ends with a diglycine sequence (GG), which defines a site for endoproteolytic cleavage to produce TUGUL, which may potentially act as a novel ubiquitin-like modifier. B. Control 3T3-L1 adipocytes, cells containing a TUG shRNA, and “rescued” cells containing the shRNA and shRNA-resistant TUG (shRNA+TUG cells) were lysed using denaturing conditions. Lysates were immunoblotted using antibodies to the TUG N and C termini, or to Hsc70 as a control, as indicated. The experiment was repeated twice with similar results.

Figure 2. Mature TUGUL has characteristics of a ubiquitin-like protein modifier. A. Sequence alignments of ubiquitin, SUMO-1, and the two ubiquitin-like regions within the TUG N terminus, UBL1, and UBL2. Conserved residues are in blue. Terminal diglycine sequences of Ubiquitin, SUMO-1, and TUGUL are highlighted in red. Additionally, TUG K134 and ubiquitin K48 are also highlighted in red. B. Alignments of the C terminal residues from several ubiquitin-like proteins, and comparison with C terminal residues from TUGUL (residues 159-164 of intact TUG). Adapted from (95). C. Flag-tagged TUGUL, TUGUL K134R, or TUGUL ΔGG (which lacks the terminal diglycine sequence) were coexpressed with GLUT4 by transient transfection of 293T cells. Cells were lysed in boiling 1% SDS, then lysates were diluted with triton X-100 and proteins were immunoprecipitated (IP) and
immunoblotted (WB) as indicated. D. Cells were transfected with flag-tagged TUGUL or TUGUL ΔGG, and HA-tagged Ubiquitin (Ub). After denaturing lysis, proteins were immunoprecipitated and immunoblotted as indicated. Experiments were repeated at least twice, with similar results.

Figure 3. Production of TUG derivatives by site-specific endoproteolytic cleavage. A. Cells were treated or not with 10 µM MG-132 for 40 min., then with insulin as indicated. After denaturing lysis, immunoblots were done as indicated. Controls show phosphorylation of the insulin receptor (IRβ p-Y) and equal loading (Hsc70, GLUT4). B. Control and shRNA cells were treated with insulin, lysed in denaturing conditions, and immunoblotted as indicated. IRβ, Insulin receptor β-chain. C. Cells were pulsed-labeled with [35S]-Cys and -Met, chased in non-radioactive amino acids, cycloheximide, and in the presence or absence of insulin, and lysed at the indicated times using denaturing conditions. Immunoprecipitations were done with the TUG C-terminus antibody, and eluted material was analyzed by SDS-PAGE and phosphorimaging. IgG was visualized by Coomassie staining (bracket), and likely altered migration of the 54 kD C-terminal product observed in other experiments (asterisk). D. Control cells, shRNA cells, and shRNA cells containing shRNA-resistant wildtype or mutated TUG were treated with insulin as indicated. After denaturing lysis, immunoblots were done as indicated. Experiments were repeated at least twice with similar results.

Figure 4. TUG processing occurs in 3T3-L1 adipocytes, but not in non-adipocyte cells. A. 293T cells and 3T3-L1 adipocytes were lysed using denaturing conditions, and immunoblots were done using the TUG C-terminus antibody. Duplicate samples are shown. B. 293T cells and 3T3-L1 cells at the indicated stages of adipocyte differentiation were lysed using denaturing conditions and immunoblotted using the TUG C-terminus antibody. Immunoblots were quantified, and the ratio of band intensities at 54 kD and 60 kD is plotted. Bars, ±SEM; n=2 for 293T cells and Day 0 3T3-L1 cells; n=6 for Day 5 and Day 10 3T3-L1 cells.

Figure 5. TUG processing occurs on membranes containing GLUT4 storage vesicles. A. 3T3-L1 adipocytes were treated with insulin as indicated, then membrane and cytosol fractions were isolated and immunoblotted to detect the TUG C- and N-termini. B. Plasma membrane (PM), light microsome (LM), and heavy microsome (HM) fractions were isolated from basal and insulin-treated control 3T3-L1 adipocytes, and from cells expressing dominant negative TUG UBX-Cter. All cells contained a myc-tagged GLUT4 reporter. Fractions were immunoblotted as indicated. Experiments were repeated at least twice with similar results.

Figure 6. TUG disruption mobilizes syntaxin-6 to the plasma membrane. A. Basal and insulin-treated control and UBX-Cter-containing 3T3-L1 adipocytes were imaged using confocal microscopy. GLUT4 was detected by a GFP tag, and syntaxin-6 by immunostaining. Scale bar, 10 µm. B. Control, shRNA, and shRNA+TUG 3T3-L1 adipocytes were treated with insulin, subjected to subcellular fractionation, and immunoblotted as indicated to detect syntaxin-6. Experiments were repeated at least twice with similar results.

Figure 7. Evidence that TUG cleavage separates GLUT4 from the Golgi matrix and requires TC10α. A. Tagged forms of GLUT4, PIST, and TUG were transfected in 293T cells as indicated. GLUT4 was immunoprecipitated, and bound proteins were analyzed by SDS-PAGE and immunoblotting as indicated. B. PIST was translated in vitro in the presence of [35S]-Cys and -Met, and was incubated with recombinant GST-TUG or with GST alone. Bound proteins were analyzed by SDS-PAGE and autoradiography. C. Basal and insulin-stimulated 3T3-L1 adipocytes stably expressing HA-PIST and GLUT4-GFP were imaged by confocal microscopy. Scale bar, 10 µm. D. GFP-tagged Golgin-160 and protein A (ZZ) -tagged TUG were transfected in 293T cells, and TUG was purified by binding to immobilized IgG. Eluates and lysates were immunoblotted as indicated. E. 3T3-L1 adipocytes were electroporated with synthetic siRNAs directed to TC10α, luciferase (as a control), or mock electroporated.
Cells were treated with or without insulin, then lysed using denaturing conditions and immunoblotted as indicated. All experiments were repeated at least twice with similar results.

Figure 8. **Quantification of TUG abundance in 3T3-L1 adipocytes.** A. Serial dilutions of recombinant GST-TUG-UBX-Cter and a bovine serum albumin standard were subjected to SDS-PAGE and staining with GelCode Coomassie. Densitometry showed that 10 µl of a 1:20 dilution of the recombinant TUG protein contained 20 ng, or about 2.5x10^{11} molecules (based on the molecular weight of GST-TUG-UBX-Cter, 47 kD). B. Immunoblots of a whole cell lysate from 3T3-L1 adipocytes and of recombinant GST-TUG-UBX-Cter were performed using an antibody directed to the C terminus of TUG. Densitometry showed that approximately 1.25x10^{10} molecules of intact TUG (60 kD) were present in 6x10^{4} cells, so that approximately 200,000 molecules of TUG are present in each 3T3-L1 adipocyte.

Figure 9. **TUG cleavage is required for regulated GLUT4 targeting in 3T3-L1 adipocytes.** A. PM, LM, and HM fractions were isolated from basal and insulin-treated cells containing TUG shRNA and shRNA-resistant proteins, as indicated, and were immunoblotted for GLUT4. Band intensities are indicated, and were normalized to GLUT4 in the HM fraction of unstimulated cells (set to 10) in each case. Similar results were obtained in at least two independent experiments for each cell line. B. Basal and insulin-stimulated 2-deoxyglucose (2-DG) uptake was measured in the indicated cells, and is plotted relative to insulin-stimulated control cells. Mean ±S.E.M., N=3, *p<0.05. C, D. Targeting of newly synthesized GLUT4 in the indicated cells was measured 18-20 h after electroporation of a dual myc- and GFP- tagged GLUT4 reporter. C. Epifluorescence microscopy was used to image cell surface and total amounts of the reporter. D. Images were quantified, and ratios were calculated and plotted relative to insulin-stimulated control cells. Mean ±S.E.M., N=16 basal and 27-30 insulin-stimulated cells in each group, *p<0.05, *p<0.01, ***p<0.001.
Fig. 1

A

TUGUL (18 kD)  42 kD C terminal fragment

N terminus  10  85  92  164  165  377  462  550 C terminus

UBL1  UBL2  UBL3/UBX

binds GLUT4 vesicles

cleavage site

hypothesized to bind an anchoring site

B

control  shRNA  shRNA+TUG

TUG N terminus

TUG C terminus

Darker

TUG C terminus

Hsc70

- 130

- 60

- 130 kD

- 54

- 42

- 70
Fig. 2

A

<table>
<thead>
<tr>
<th>Ubiquitin/1-76</th>
<th>1:...........</th>
<th>KCITKTLLGKTLTLQVTIPEATDPITIENVAKATQD</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUMO1/1-97</td>
<td>1:...........</td>
<td>MSDKAPKDEDGDKKTELQERVRGQSSQEHHKMKMTLKKKLESYCQ</td>
</tr>
<tr>
<td>TUG-UBL1/9-85</td>
<td>1:...........</td>
<td>GSATYIAVNGRRTVQY4PSTVYVLQVLEDTCR</td>
</tr>
<tr>
<td>TUG-UBL2/86-164</td>
<td>1:...........</td>
<td>EGPEN1VRIAFQFLDCRQDAFCSRRQITWEILSHFAQ</td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>Ubl</th>
<th>C-terminal sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ubiquitin</td>
<td>LRLRGG</td>
</tr>
<tr>
<td>ISG15</td>
<td>LRLRGG</td>
</tr>
<tr>
<td>NEDD8/RUB1</td>
<td>LALRGG</td>
</tr>
<tr>
<td>TUGUL</td>
<td>LGTGG</td>
</tr>
<tr>
<td>SUMO1</td>
<td>QEQTGG</td>
</tr>
<tr>
<td>SUMO2/3</td>
<td>QQTGG</td>
</tr>
<tr>
<td>FUB1/MNSF-β/FAU</td>
<td>GRMLGG</td>
</tr>
<tr>
<td>FAT10</td>
<td>SYCGG</td>
</tr>
<tr>
<td>URM1</td>
<td>STLHG</td>
</tr>
<tr>
<td>UFM1</td>
<td>PRDRVG</td>
</tr>
<tr>
<td>ATG12</td>
<td>KSGANG</td>
</tr>
<tr>
<td>GABARAP-L2/ATG8</td>
<td>GENTFG</td>
</tr>
</tbody>
</table>

C

flag-TUGUL: 
- + - + - + - 
flag-TUGUL K134R: 
- + - + - + + 
flag-TUGUL ΔGG: 
- - - + - + + 
GLUT4-7myc: 
- - - + + + +

D

flag-TUGUL: 
- + + - - + 
flag-TUGUL ΔGG: 
- - - + + + 

IP flag-TUGUL, WB HA-Ub: 
- + + + + + + 

kD:
- 191
- 97
- 64
- 51
- 34
- 28
- 19

lysate, WB myc (GLUT4)

---

lysate, WB HA-Ub

kD:
- 26
- 18
- 38
- 28
- 17
- 14
- 8
Fig. 3

A

insulin (min.)

control + MG-132

intact TUG

modified cleavage product

TUG C terminus

unmodified cleavage product

TUG N terminus

intact TUG

IRβ p-Y

Hsc70

GLUT4

B

time after insulin (min.)

control cells

shRNA cells

intact TUG

modified cleavage product

TUG C terminus

intact TUG

modified cleavage product

unmodified cleavage product

TUG N terminus

intact TUG

IRβ

C

chase time (min.): 0 5 10 20 40

insulin: – + – + – +

intact TUG precursor

64 kD

51 kD

unmodified C terminal cleavage product

D

insulin (min.): 0 5 10 20

Control shRNA shRNA+TUG WT shRNA+TUG GGAA shRNA+TUG S165M shRNA+TUG K380R

60 kD (intact)

54 kD (cleavage product)

42 kD (cleavage product)

TUG C terminus

(darker exposure)

Hsc70

60 kD (intact)

54 kD (cleavage product)

70 kD

MG-132

control

+ MG-132
The figure shows a Western blot (WB) of TUG C-terminus for 293T cells and 3T3-L1 adipocytes. The blot indicates the presence of bands at 60 kD, 54 kD, and 42 kD.

**A**
- 293T cells
- 3T3-L1 adipocytes

**B**
- A bar graph showing the ratio of abundances of 54 kD C-terminal product to 60 kD intact TUG.
  - 293T cells
  - Day 0 3T3-L1
  - Day 5 3T3-L1
  - Day 10 3T3-L1

The graph indicates a significant increase in the ratio of the 54 kD product to the 60 kD intact TUG over time in 3T3-L1 adipocytes compared to 293T cells.
Fig. 5

A


fraction: membrane  cytosol  membrane

insulin (min):  0  8  20  60  0  8  20  60  0  8  20  60

TUGUL-modified protein →

intact TUG →

42 kD C terminal cleavage product →

darker exposure →

intact TUG →

42 kD C terminal cleavage product →

B

GLUT4 (myc)

TUG C terminus

TUGUL-modified protein →

TUG N terminus

GLUT1

Syntaxin-6

Syntaxin-16

Vti1a

VAMP3

VAMP4

PIST

Control PM LM HM TUG UBX-Cter PM LM HM

insulin:  -  +  +  -  -  -  -  +  +  +  +  +

- 55

- 191

- 64

- 51

- 39

- 28

- 19

- 191

- 97

- 64

- 51

- 39

- 28

- 19

- 50

- 30

- 35

- 29

- 14

- 16

- 55
Fig. 6

A

<table>
<thead>
<tr>
<th></th>
<th>GLUT4 (green)</th>
<th>Syntaxin-6 (red)</th>
<th>merged</th>
</tr>
</thead>
<tbody>
<tr>
<td>control basal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>control insulin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TUG UBX-Cter</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>basal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>insulin</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>insulin:</th>
<th>PM</th>
<th>LM</th>
<th>HM</th>
</tr>
</thead>
<tbody>
<tr>
<td>control</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>shRNA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>shRNA+TUG</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Fig. 7**

**A**

<table>
<thead>
<tr>
<th>Sample Type</th>
<th>WB</th>
<th>IP GLUT4 (myc), WB PIST (HA)</th>
<th>IP GLUT4 (myc), WB PIST (HA)</th>
<th>lysate, WB TUG (flag)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLUT4-7myc</td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>HA-PIST</td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>flag-TUG</td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

**B**

- **35S autoradiograph**
  - PIST
  - GST-TUG

- **Coomassie**
  - GST
  - GST-TUG

**C**

- **GLUT4 (green)**
  - Basal
  - Insulin

- **PIST (red)**
  - Basal
  - Insulin

- **merged**

**D**

<table>
<thead>
<tr>
<th>Sample Type</th>
<th>WB</th>
<th>IP TUG, WB Golgin-160</th>
<th>lysate, WB Golgin-160</th>
</tr>
</thead>
<tbody>
<tr>
<td>GFP-Golgin-160</td>
<td></td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>ZZ-flag-TUG (intact)</td>
<td></td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>ZZ-flag-TUG UBX-Cter</td>
<td></td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

**E**

- **mock**
- **luciferase**
- **TC10-1**
- **TC10-2**

<table>
<thead>
<tr>
<th>insulin</th>
<th>TUG</th>
<th>TC10α</th>
<th>TUG (lighter)</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>
Fig. 8

A  Coomassie-stained gels

<table>
<thead>
<tr>
<th>Mass (ng)</th>
<th>400</th>
<th>20</th>
<th>10</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>GST-TUG-UBX-Cter</td>
<td>-47 kD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albumin standard</td>
<td>-60 kD</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B  Immunoblots

<table>
<thead>
<tr>
<th>Dilution</th>
<th>1:1</th>
<th>1:10</th>
<th>1:20</th>
<th>1:200</th>
<th>1:400</th>
</tr>
</thead>
<tbody>
<tr>
<td>GST-TUG-UBX-Cter</td>
<td>-47 kD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>intact TUG (in 6x10^4 cells)</td>
<td>-60 kD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Fig. 9

A

<table>
<thead>
<tr>
<th>Treatment</th>
<th>PM</th>
<th>LM</th>
<th>HM</th>
</tr>
</thead>
<tbody>
<tr>
<td>control</td>
<td>0.3</td>
<td>2.7</td>
<td>1.0</td>
</tr>
<tr>
<td>shRNA</td>
<td>7.8</td>
<td>3.0</td>
<td>1.2</td>
</tr>
<tr>
<td>shRNA+TUG WT</td>
<td>2.4</td>
<td>1.4</td>
<td>1.5</td>
</tr>
<tr>
<td>shRNA+TUG GGAA</td>
<td>0.2</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>shRNA+TUG S165M</td>
<td>1.3</td>
<td>0.6</td>
<td>1.5</td>
</tr>
</tbody>
</table>

B

**Relative 2-DG uptake**

C

Red: cell surface GLUT4
Green: total GLUT4

D

**Normalized ratio of surface/total GLUT4**
Endoproteolytic cleavage of TUG regulates GLUT4 glucose transporter translocation
Jonathan S. Bogan, Bradley R. Rubin, Chenfei Yu, Michael G. Loffler, Charisse M. Orme,
Jonathan P. Belman, Leah J. McNally, Mingming Hao and James A. Cresswell

J. Biol. Chem. published online May 18, 2012

Access the most updated version of this article at doi: 10.1074/jbc.M112.339457

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 0 references, 0 of which can be accessed free at
http://www.jbc.org/content/early/2012/05/18/jbc.M112.339457.full.html#ref-list-1